• SPX
  • $5,730.87
  • 0.61 %
  • $34.93
  • DJI
  • $41,975.63
  • 0.05 %
  • $21.38
  • N225
  • $38,937.54
  • -1 %
  • -$395.20
  • FTSE
  • $8,190.61
  • -1.36 %
  • -$113.01
  • IXIC
  • $18,102.66
  • 1 %
  • $178.75
Stoke Therapeutics, Inc. (STOK) Stock Price, News & Analysis

Stoke Therapeutics, Inc. (STOK) Stock Price, News & Analysis

Currency in USD Disclaimer

$12.28

$0.88

(7.68%)

Day's range
$11.43
Day's range
$12.41
50-day range
$11.15
Day's range
$16.15
  • Country: US
  • ISIN: US86150R1077
52 wk range
$3.35
Day's range
$17.58
  • CEO: Dr. Edward M. Kaye M.D., Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 3.26
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (STOK)
  • Company Stoke Therapeutics, Inc.
  • Price $12.28
  • Changes Percentage (7.68%)
  • Change $0.88
  • Day Low $11.43
  • Day High $12.41
  • Year High $17.58

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/05/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $28.50
  • High Stock Price Target $58.00
  • Low Stock Price Target $20.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.42
  • Trailing P/E Ratio -6.14
  • Forward P/E Ratio -6.14
  • P/E Growth -6.14
  • Net Income $-104,699,000

Income Statement

Quarterly

Annual

Latest News of STOK

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.